Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity

G. Y. Ku, Akhil Chopra, Gilberto de Lima Lopes

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Hepatotoxicity secondary to gefitinib, an oral tyrosine kinase inhibitor (TKI) against the epidermal growth factor receptor (EGFR), is under-appreciated, even though it has a reported incidence of 10-20% in phase II trials. Methods/results: We present two patients with non-small cell lung cancer (NSCLC) who developed grade 2/3 hepatotoxicity starting between 4 and 6 weeks after initiation of gefitinib, with toxicity peaking between 10 and 20 weeks. Both patients were switched to treatment with erlotinib, another EGFR TKI, without further development of hepatotoxicity. One patient with measurable metastatic disease achieved a durable near complete response while on erlotinib. The other patient experienced recurrence of hepatotoxicity when gefitinib was briefly reintroduced. Conclusions: Patients with NSCLC receiving gefitinib should undergo routine monitoring of liver enzymes. For those who develop gefitinib-induced hepatotoxicity but are otherwise deriving clinical benefit, consideration can be given to switching to erlotinib.

Original languageEnglish (US)
Pages (from-to)223-225
Number of pages3
JournalLung Cancer
Volume70
Issue number2
DOIs
StatePublished - Nov 1 2010

Keywords

  • Erlotinib
  • Gefitinib
  • Hepatotoxicity
  • Liver enzyme
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity'. Together they form a unique fingerprint.

Cite this